BeiGene Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (16)

Latest Posts

About This Stock More About This Stock
Week In Review: Hansoh Plans Hong Kong IPO To Raise Up To $1 Billion
Article By: ChinaBio® Today
Saturday, April 13, 2019 4:09 PM EDT
Hansoh Pharma, an established drug company, has filed for a Hong Kong IPO, and is rumored to seek between $500 million and $1 billion in new capital. It's a profitable drug company with $1.1 billion in revenue and more than $280 million in profits.
In this article: ROG, BGNE, BAYN, BAYN
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By: ChinaBio® Today
Saturday, March 9, 2019 4:13 PM EDT
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
In this article: CASI, BGNE, GRFS, NVO
Read
Week In Review: Yantai's MabPlex Raises $59 Million To Expand CDMO Services
Article By: ChinaBio® Today
Sunday, January 20, 2019 10:38 AM EDT
MabPlex, a biologics CDMO, raised $59 million in a Series A round from SDIC Venture Fund and Shenzhen Venture Capital. MabPlex offers biologics development and manufacturing services, including mAbs, recombinant proteins, ADCs and bispecifics.
In this article: AZN, IRWD, CBMG, BGNE
Read
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By: ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EDT
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
In this article: LLY, HCM, BGNE, MGNX, ZLAB, TCON, ZYME, BHVN
Read
Week In Review: Biosense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy
Article By: ChinaBio® Today
Saturday, October 13, 2018 4:59 PM EDT
Biosense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs, following a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid.
In this article: MEIP, BGNE
Read

PARTNER HEADLINES

Latest Tweets for $BGNE

No tweets yet!